Dimension Therapeutics, Inc. (NASDAQ:DMTX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.

On May 2, 2017, Dimension Therapeutics, Inc. (the “Company”) entered into a Second Lease Amendment to the Lease (the “Second Lease Amendment”) with Rivertech Associates II, LLC, relating to the lease of approximately 15,000 rentable square feet of office and laboratory space in Cambridge, Massachusetts. The Second Lease Amendment amends the Indenture of Lease between the Company and Rivertech Associates II, LLC, dated March 11, 2014, and the First Lease Amendment to the Lease dated as of October 22, 2014 (the “Lease”).

Under the Second Lease Amendment, the term of the Lease is extended for an additional two years, commencing on February 1, 2018. The Company will pay annual rent of $64.00 per rentable square foot for the first year and $66.00 per rentable square foot for the second year. The Company is also responsible for its pro rata share of real estate taxes, operating expenses and utilities. Upon certain terms and conditions set forth in the Second Lease Amendment, the Company has the right to extend the Lease for one additional five year period.

Except as specifically amended by the Second Lease Amendment, the Lease remains in full force and effect.

The foregoing description of the Lease Second Amendment does not purport to be complete and is subject to, and qualified in its entirety by, the full text of such agreement, a copy of which will be filed as an exhibit to the Company’s quarterly report on Form 10-Q for the quarter ended June 30, 2017.

About Dimension Therapeutics, Inc. (NASDAQ:DMTX)

Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company’s gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company’s lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Dimension Therapeutics, Inc. (NASDAQ:DMTX) Recent Trading Information

Dimension Therapeutics, Inc. (NASDAQ:DMTX) closed its last trading session down -0.05 at 1.35 with 52,595 shares trading hands.